The statistical design and analysis of pandemic platform trials: Implications for the future
Christopher J. Lindsell(Clinical Research Institute), Lisa M. LaVange(University of North Carolina at Chapel Hill), Thomas G. Stewart(University of North Carolina at Chapel Hill), Matthew S. Shotwell(Vanderbilt University Medical Center), Sonia Thomas, Michael A. Proschan(National Institute of Allergy and Infectious Diseases), Scott Berry(Queen's University), Prasanna Jagannathan(Palo Alto University), Carlee Moser(Harvard University), Karen Price(Eli Lilly (United States)), Birgit Grund(University of Minnesota), Giota Touloumi(National and Kapodistrian University of Athens), Kevin J. Anstrom(University of North Carolina at Chapel Hill), Eric Leifer(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael D. Hughes(Virginia Tech), Erica Brittain(Johns Hopkins University), Frank E. Harrell(Vanderbilt University Medical Center), Nancy L. Geller(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 2
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818